Alnylam Pharmaceuticals Hits 52-Week Low at $273.17 Amid Market Turmoil

Alnylam Pharmaceuticals, Inc. has reached a significant milestone by touching a new 52-week low of USD 273.17 on June 18, 2026. This marks a notable decline from its previous high of USD 495.31, reflecting the stock's recent volatility within the pharmaceuticals and biotechnology sector. Despite this downturn, Alnylam Pharmaceuticals has demonstrated a robust one-year performance, achieving an impressive 81.2%, significantly outperforming the S&P 500, which recorded a 25.41% increase over the same period. The company's market capitalization stands at USD 42,089 million, categorizing it as a mid-cap entity within its industry. Financial metrics indicate a price-to-earnings (P/E) ratio of 118.00, while the return on equity is a strong 45.14%. However, the company does not offer a dividend yield, and its debt-to-equity ratio is reported at -0.21, suggesting a unique financial structure. As Alnylam Pharmaceuticals navigates this challenging phase, its performance metrics will be closely monitored by market participants.